| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SCGN |
| Uniprot No | O76038 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-276aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMDSSREPTLGRLDAAGFWQVWQRFDADEKG YIEEKELDAFFLHMLMKLGTDDTVMKANLHKVKQQFMTTQDASKDGRIRM KELAGMFLSEDENFLLLFRRENPLDSSVEFMQIWRKYDADSSGFISAAEL RNFLRDLFLHHKKAISEAKLEEYTGTMMKIFDRNKDGRLDLNDLARILAL QENFLLQFKMDACSTEERKRDFEKIFAYYDVSKTGALEGPEVDGFVKDMM ELVQPSISGVDLDKFREILLRHCDVNKDGKIQKSELALCLGLKINP |
| 预测分子量 | 34 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SCGN(Secretagogin)重组蛋白的3条参考文献示例(注：内容为模拟概括，实际文献需通过学术数据库检索确认)：
1. **文献名称**：*Recombinant Secretagogin expression and its role in insulin secretion*
**作者**：Wagner, L., et al.
**摘要**：研究报道了人源SCGN重组蛋白在大肠杆菌中的高效表达与纯化，并验证其通过调控钙信号通路促进胰岛β细胞胰岛素分泌的功能。
2. **文献名称**：*Structural characterization of recombinant Secretagogin using X-ray crystallography*
**作者**：Petersson, C., & Johansson, K.
**摘要**：通过X射线晶体学解析了重组SCGN蛋白的三维结构，揭示了其钙离子结合位点的构象变化及其对神经内分泌细胞活性的调控机制。
3. **文献名称**：*Secretagogin as a biomarker: Recombinant protein-based detection in neurodegenerative diseases*
**作者**：Zhang, Y., et al.
**摘要**：开发了基于重组SCGN蛋白的ELISA检测方法，证实其在阿尔茨海默病患者脑脊液中的表达水平异常，提示其作为神经退行性疾病标志物的潜力。
建议通过PubMed或Web of Science以“Secretagogin recombinant protein”为关键词检索最新文献获取具体信息。
Secretagogin (SCGN) is a calcium-binding protein belonging to the EF-hand protein superfamily, first identified in pancreatic β-cells and neuroendocrine tissues. It is characterized by six EF-hand domains, though only four bind calcium ions. SCGN plays roles in calcium signaling, exocytosis, cell differentiation, and protection against oxidative stress. Its expression is prominent in the brain, pancreas, and endocrine cells, linking it to neurological disorders (e.g., Alzheimer’s disease), diabetes, and cancers.
Recombinant SCGN is produced using biotechnological platforms like *E. coli* or mammalian cell systems, enabling scalable, pure protein yields. This engineered protein retains native structural and functional properties, allowing researchers to study its interactions with cytoskeletal proteins, ion channels, and transcription factors. For example, SCGN modulates insulin secretion by regulating SNARE complex assembly in β-cells, highlighting its therapeutic potential in diabetes. In neuroscience, recombinant SCGN aids in exploring its neuroprotective effects and biomarker utility in neurodegenerative diseases.
Commercial production of recombinant SCGN also supports diagnostic applications, such as antibody development for detecting neuroendocrine tumors. Ongoing research focuses on its dual roles in cell survival and apoptosis, particularly in cancer contexts, where SCGN may act as a tumor suppressor or promoter depending on tissue type. Overall, recombinant SCGN serves as a critical tool for dissecting calcium-mediated cellular mechanisms and developing targeted therapies.
×
